Know Labs Inc (PK) (KNWN) Quote

All grifts crash sooner or later. The pumpers who got out thank you.

KNW changed to KNWN. Delisted from the NYSE to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

Another pump and dump in the face of yet another scumbag stand by financing. TOTAL TRASH

knw...........................https://stockcharts.com/h-sc/ui?s=knw&p=W&b=5&g=0&id=p86431144783

Here we go again...... 2015 all over again. I didn't think this would happen again. Just hope it isn't a 1 for 150 again. 

Dead money.  Reverse Split

Indeed. Recycled. Lack of updates have shareholders clinging.

Youtube indicates that this video was posted 2 weeks ago but I was a little confused by some of the comments versus the timing of the interview.
- Early on in the video Ron mentioned Phil Boshua's role in the early development and told the moderator he should speak with him... I had the impression that there was some animosity between Phil and Know Labs after his departure.
- Later in the video Ron mentioned that they wanted to uplist to NASDAQ... if they are already listed on NYSE why would they be talking about a NASDAQ listing?
- Also, Ron mentioned that Dexcom has a $60B market cap... 2 weeks ago Dexcom's market cap was about $30B and the $60B market cap was from 6 months ago.

Know Labs - Revolutionizing Non-Invasive Medical Diagnostics

It's certainly been a slow journey but many of the current longs have accumulated when the stock was low-priced. My cost basis is below 50 cents so I'm not too worried. I expect this will be a classic example of Buffett's maxim that "The stock market is designed to transfer money from the active to the patient".

Thomas Edison has been exposed for orchestrating one of the most audacious cons in industrial history, crafting hundreds of failed lightbulbs to fleece investors out of millions while feigning imminent breakthroughs. The so-called "Wizard of Menlo Park" employed a legion of "scientific consultants" to inflate his failure count, ensuring that his investors remained perpetually on the hook while his own fortune flourished. And then, in a final evil twist, he succeeded in creating the first working lightbulb-- thereby defrauding the honorable shorts and rewarding the scoundrels who supported him all along.

Longs have officially been fucked over by Ron. Thanks all 😊

Hate to say "I told y'all so." You're welcome.

So they demolish the stock price to get the new international investors on board???Just goes to show that little guys don't stand much of a chance as companies like this dilute at will and rs as part of their growth strategy. They couldn't raise money at .50,.60.70 cents verses who knows how low the offering will ultimately be?

They only tapped into $4M of the lind deal. Don’t listen to that Ham guy, he has no idea what he’s talking about.

My guess is new offering is being bought up by foreign investors since they brought on the new international president.

There is a s-1 that has been filed. Blank as to $ amount from what i can tell. It showed as Restricted stock until the company clears fda. But no matter is still very confusing, why do such when you just did a 12$ mil deal with Lind Partners? Maybe Phil back to angry and dumping his stash again.

Is this price collapse just short sellers bringing it down from $.82 to sub $.40 now or is there some fundamental news behind this drop?

Between 2005 and 2018, the FDA cleared several CGM devices with a wide range of MARDs: 17.2%, 13.6%, 18.3%, and 8.7%-9.14%.

https://link.springer.com/article/10.1007/s41745-022-00348-3

The decision to clear a medical device depends on a variety of factors including safety, efficacy, and overall benefit-risk profile. If a new CGM demonstrates substantial advantages despite a slightly higher MARD, it could still be favorably reviewed.

In my opinion, the non-invasiveness, lack of consumables, and overall lower cost of the KNOW Labs device, along with consistent MARDs in the 11-12% range, makes it highly likely to receive FDA clearance in the near future.

Saw an interesting journal article comparing the MARD between the Dexcom G7 and the the Abbott FreeStyle 3. In past discussions on this board, there has been concern that the MARD of the KnowU device was only around 11.1% while Dexcom claimed a MARD of 8.2% for the G7.

The journal paper from the beginning of this year, Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring Systems, described testing that showed the true MARD of the G7 to be 13.6%. The journal article also noted that the MARD was over 27% in low glucose ranges (mg/dL

Leo Trautwein Presents Know Labs at LSI USA '24

Great video. He goes into much more detail about the design and testing process. I believe they're on track to make significant progress.

No. I am not. Sorry. Just saw this now.

Are Non-Invasive CGMs the Future? Best Interview Steve Kent

“Kent said in the video that Know Labs is planning to further pare down the wearable device housing the sensor, though the company noted in Tuesday’s announcement that the sensor itself is the same one it will eventually be submitting to the FDA.”

https://www.fiercebiotech.com/medtech/know-labs-finalizes-noninvasive-glucose-sensor-design-sets-sights-fda-pivotal-trial

KNW will never make those marks. You should have shorted when the volume enabled.

Thanks so much for the Adult explanation. It's good to know we have smart and intelligent people following KNW. It is good to know that KNW is in the area and there are people rooting for this tech to succeed. This sounds exciting and looking forward to a better future for diabetics.

the G7 and it seems to be able to give a MARD # of 8.5 and our Uband comes in at 11.1You can find the details of the Dexcom G7 study at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208857/ and, if you review the study you will see that the the 8.2% MARD they report is based on a much different study than was conducted by KNW. I'm not a medical researcher but there seems to be enough of a difference in the testing to suggest that the two MARD values should not be compared - a couple of differences that seemed to jump out are:

- The Dexcom study used only participants that "had T1D, intensive insulin therapy T2D (T2D-IIT), or nonintensive insulin therapy T2D (T2D-NIIT)". Essentially, their study only involved Type 1 or Type 2 diabetics that were receiving treatment. The Know Labs MARD seems to include non-diabetics, pre-diabetics, Type 1 diabetics, and Type 2 diabetics. I would expect different MARD readings based on the population differences

- Most of the G7 MARD was based on normal usage across the 11 days that the device is working (the device has to be replaced on day 11). The MARD for the G7 was as high as 12.9% on the first day and tended to drop significantly by day 11 - the 8.2% MARD that they report is an average MARD across different days. The KNW MARD was based on readings after a glucose tolerance test. Again, you would expect different MARD readings as a result of different test protocols

I'm guessing that the testing that will be performed by KNW for FDA approval will be more rigorous and should provide results that can better compare to the performance reported for other devices on the market. In addition, the G7 device is the latest generation of Dexcom devices so you would hope that significant improvement has been made in the accuracy of the technology... the KnowU device is still undergoing development and should also continue to improve in accuracy. Finally, I don't think the KnowU needs to be the most accurate CGM device right out of the gate - if the accuracy is in the same ballpark then the cost and convenience benefits will probably be the biggest drivers of approval and adoption.

So, Squide your telling me that it's great that Know labs will fail and poor Diabetics will have to continue to pay 5 to $700. per month for a sensor that monitors their blood sugar. You must work for Dexcom or your a pretty poor Human Being.

They need a MARD of below 10% and they’ve gotten it down to ~11%. They’re now about one percent away from creating the first non-invasive CGM— which would instantly leapfrog the competition.

CGMs are a 4.6 billion dollar market that’s estimated to reach 18 billion by 2028.

As long as they keep making measurable progress I will happily wait. :)

Either you or Ron will die before these guys are able to bring on revenue. Sorry

OK guys and gals. We faithfull for many years are finally seeing hard numbers come out on the efficacy of that wonderfull piece of technology that has been invented and we see the first generation of the product with our very own eyes. The question on my mind is is it good enough to be competitive. I checked on the MARD #s of the G7 and it seems to be able to give a MARD # of 8.5 and our Uband comes in at 11.1. Does anyone out there have a clue as to what would be a good enough MARD for the FDA? It does seem that minuturizing the lab unit to the Uband unit has increased the MARD from 6.5 to 11.1 and I know the lab test is not real world but can that be improved on? I sure hope somebody in the know can answer this. Sure hoping this comes to market soon. I ain't gettin any youger. Been here for 14 years now and still waiting and hoping.

This stock plunges more often than a Pelican behind a school of fish. I guess investors are tired of waiting for the oft-promised but not-yet-delivered CGM device.

Funding from Lind. Oh boy, who's seen their track record?!

KNW......................................https://stockcharts.com/h-sc/ui?s=KNW&p=W&b=5&g=0&id=p86431144783

With todays news, I can't believe anyone is selling!

What Happened today. WOW. Somebody has to know something. Up 40% in one day. That's amazing, and yet no comments. Where is everybody/

"John Cronin was added to the Know Labs Board in November 2023 to play a pivotal role in its growth.
He is a Rock Star.
 
Why would someone like this join Know Labs?

“John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin began his career at IBM where he was the sole inventor of breakthrough chip design technology that became the company’s most valuable patent, generating $500 million in revenue.

He went on to create the IBM Patent Factory and grew IBM’s patent portfolio from ninth to number one in the world. He played a pivotal role in increasing IBM’s patent licensing revenue from $30 million to over $2 billion a year. Cronin has been a strategic advisor and consultant to Know Labs, supporting the company’s expanding patent portfolio from 86 to 246 patents issued, pending and in process over the last twelve months, increasing its global leadership in the non-invasive blood glucose monitoring category.”

Biography

John Cronin is Chairman and CEO of ipCapital Group, Inc. (“ipCG”), an intellectual property consulting firm. Mr. Cronin founded ipCG in 1998.

Mr. Cronin and ipCG have worked with over 1,200 companies and approximately 10% of the Fortune 500 companies, hundreds of mid-size companies, and hundreds of startups and governmental laboratories. Over the years, Mr. Cronin has become a respected thought leader among executives who wish to align business issues with IP and translate strategies into actionable financial results. Mr. Cronin has inspired and trained thousands of engineers and scientists in the best practices of “how to invent.”




Mr. Cronin has authored greater than 1500 patents and applications across hundreds of technology spaces, leveraging the ipCapital Methodology."

Yeah. What was that?! Does someone know something? I wonder if something leaked.

$KNW Kaboom 💥

I'm so glad Know Labs empathizing the children. My boy was 2 1/2 when he came down with type 1.

During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.

How AI and ML Are Scaling Data Collection to Transform Medical Monitoring
Steve Kent, is the Chief Product Officer at Know Labs.
https://www.unite.ai/how-ai-and-ml-are-scaling-data-collection-to-transform-medical-monitoring/

Oh, I check in now and then. I sold enough stock for a 200% profit, but I’m hanging on to all the rest— which is plenty.

That MARD is getting close. Best bet, in my opinion, is to measure against blood glucose readings instead of Dexcom, which isn’t perfect, but that will mean a longer approval process.

It will be worth it in the end. :)

$KNW - boom 💥

Aren't you in Rockley too?

Because the largest KNW shareholder purchased 14 million shares of the private placement. See Form 13D

Why do I get the feeling that the 25cent shares are long gone?

I had signed up for it but am unable to attend. This is the closest conference to me so far. It is in the Bay Area. I live in Socal. Still about 400 Miles away. I was definitely going to track them down. Can't go unfortunately. This is not the timeline that I imagined back in 2018 when Phil announced the tech. The worst part is the dilution. I will be pissed beyond reason if they RS us again. My patience is finally wavering.

Just about 25 years of R&D, close to $130m to monetize what?

Investors getting slaughtered

Last year this stock traded close to $3 premarket during the last offering, now 25 cents

CEO should at least send out condolence cards to his loyal shareholders

You're at Imagine, correct? I'd track these clowns down and ask why they are so piss poor at managing a project and ask for a reasonable timeline. Ask Ron how end of 2023 turned to 2025-2026. I'd also ask why insiders aren't buying at current prices if this is "the holy grail of the medical industry."
I think the market will have many opportunities to buy at current price or lower as they continue to dilute until 2026.

This is actually crazy. "Preparation" for De novo. 2026???????????????
As you know, I am a 12 year shareholder. Are we seeing the most elaborate shell game ever perpetrated? Keep leading us on??